Laboratoire de Diagnostic Génétique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), CNRS UMR-7104, Inserm U964, Université de Strasbourg, Strasbourg, France.
Eur J Hum Genet. 2018 Jul;26(7):996-1006. doi: 10.1038/s41431-018-0096-4. Epub 2018 Apr 26.
High-throughput sequencing (HTS) of human genome coding regions allows the simultaneous screen of a large number of genes, significantly improving the diagnosis of non-syndromic intellectual disabilities (ID). HTS studies permit the redefinition of the phenotypical spectrum of known disease-causing genes, escaping the clinical inclusion bias of gene-by-gene Sanger sequencing. We studied a cohort of 903 patients with ID not reminiscent of a well-known syndrome, using an ID-targeted HTS of several hundred genes and found de novo heterozygous variants in TCF4 (transcription factor 4) in eight novel patients. Piecing together the patients from this study and those from previous large-scale unbiased HTS studies, we estimated the rate of individuals with ID carrying a disease-causing TCF4 mutation to 0.7%. So far, TCF4 molecular abnormalities were known to cause a syndromic form of ID, Pitt-Hopkins syndrome (PTHS), which combines severe ID, developmental delay, absence of speech, behavioral and ventilation disorders, and a distinctive facial gestalt. Therefore, we reevaluated ten patients carrying a pathogenic or likely pathogenic variant in TCF4 (eight patients included in this study and two from our previous ID-HTS study) for PTHS criteria defined by Whalen and Marangi. A posteriori, five patients had a score highly evocative of PTHS, three were possibly consistent with this diagnosis, and two had a score below the defined PTHS threshold. In conclusion, these results highlight TCF4 as a frequent cause of moderate to profound ID and broaden the clinical spectrum associated to TCF4 mutations to nonspecific ID.
高通量测序(HTS)可对人类基因组编码区进行同时检测,从而显著提高非综合征性智力障碍(ID)的诊断率。HTS 研究允许重新定义已知致病基因的表型谱,从而避免了逐个基因 Sanger 测序的临床纳入偏倚。我们使用数百个基因的 ID 靶向 HTS 对 903 名不伴有明显综合征的 ID 患者进行了研究,在 8 名新患者中发现了 TCF4(转录因子 4)的新生杂合变异。将本研究的患者与之前大规模无偏 HTS 研究的患者进行整合,我们估计携带致病 TCF4 突变的 ID 患者的比例为 0.7%。到目前为止,TCF4 分子异常被认为是导致 Pitt-Hopkins 综合征(PTHS)的一种综合征形式 ID,PTHS 具有严重的 ID、发育迟缓、无言语、行为和通气障碍以及独特的面部特征。因此,我们根据 Whalen 和 Marangi 定义的 PTHS 标准,重新评估了 10 名携带 TCF4 致病性或可能致病性变异的患者(包括本研究的 8 名患者和我们之前 ID-HTS 研究的 2 名患者)。事后,5 名患者的 PTHS 评分高度提示 PTHS,3 名患者可能符合该诊断,2 名患者的评分低于定义的 PTHS 阈值。总之,这些结果突出了 TCF4 作为中度至重度 ID 的常见原因,并将与 TCF4 突变相关的临床谱拓宽至非特异性 ID。